Based on cash, cash equivalents and marketable securities, as of December 31, 2023, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into the second half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMRX:
- Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Immuneering receives FDA Fast Track designation for IMM-1-104
- Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
- Immuneering Announces Participation in February Investor Conferences
